Le Lézard
Classified in: Health
Subject: SVY

Global Insulin Pump Market, Users, Forecast, Reimbursement Policy (Countries: US, Canada, Germany, Australia, France, Netherlands, Switzerland, Sweden, Israel, UK & Japan) Clinical Trials, Training Model, Companies Analysis


LONDON, Oct. 19, 2017 /PRNewswire/ -- The growth of diabetes management policy and expansion of diabetes knowledge over the world, the market for insulin pump will develop positive outlook in future year. With the assistance of insulin pump patients deal with their diabetes with a high level of proficiency without visiting their doctor.



Download the full report: https://www.reportbuyer.com/product/5142066



Global insulin pump market is growing due to different growth drivers such as ageing population, rise in diabetic population and evolution of new products. Though, the market faces certain hurdles like a threat from the implantable insulin pump, the high cost of insulin pumps, complicated software used in insulin pumps and invention of artificial pancreas etc.

US controls more than 50% of the Global Insulin Pump Market
In the United States, Insulin Pump has now become a favored and renowned device for Type1 diabetes patients. The spontaneity of using insulin pump is gaining inclusive appreciation in the market as insulin delivery systems. The better execution of public & private reimbursement policy about the insulin pump makes the United States world's largest insulin pump market.

Germany has the Biggest Number of Insulin Pump Clients in Europe
Germany records the highest number of insulin pump user due to its overall population and relatively number of type 1 diabetes patients in Europe.

Reimbursement Policy Analysis
The report studies Insulin pump reimbursement policy of 11 countries (United States, Canada, Germany, Australia, France, Netherlands, Switzerland, Sweden, Israel, United Kingdom & Japan). US and Australia reimbursement policy is considered to be best among all the countries.

Global Insulin Pump Market, Users, Forecast, Reimbursement Policy (Countries: US, Canada, Germany, Australia, France, Netherlands, Switzerland, Sweden, Israel, UK & Japan) Clinical Trials, Training Model, Companies Analysis is the 2nd edition published by Renub Research on Insulin Pump Market. This 240 page report with 123 Figures and 12 Tables provides a detailed and comprehensive insight of the Global Insulin Pump Market.

Scope of the Report
? Insulin Pump Market & Forecast: This report comprises of insulin pump market and volume of user of 11 countries. Market data from 2010 to 2016 and Forecast period from 2017 to 2024.
? Reimbursement Policy: Report covers the details of separate reimbursement policy for 11 countries including Insulin Pumps, Diabetes Supplies (Blood Glucose Devices, Test Strips, Lancets, Disposable Needles, Syringe, Ketone Urine Testing Strips, and Pen Delivery etc)
? Training Models: This topic shows through flow chart method, how a company provides training. This segment companies Training program for its staff includes physicians, Certified Diabetes Educators (including nurse educators, dietitians and exercise physiologists) and support staff with expertise in insulin pump therapy and Training program for patients have been described through flow chart method. In total 4 companies Medtronic, Insulet Corporation, Animas Corporation & Tandem Diabetes Care Training program has been studied in the report.
? Differentiation Points of Insulin Pump Products: This report discusses about pros and cons of the insulin pumps: Animas Vibe, Medtronic 530G with Enlite, Insulet OmniPod, Tandem t:slim, Roche Accu-Chek Combo.
? Clinical Trials of Insulin Pumps: This report covers the details of clinical trials results for companies on Insulin Pumps. Following are the details of the companies associated with insulin pumps- Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche and Animas Corporation.
? Companies Analysis: In this report 3 companies have been discussed from the following points: Overview, Product Details, Insulin Pump Sales Analysis and Latest Development & Trends in their insulin pumps. The three companies studied in the report are as follows: Medtronic, Insulet Corporation and Tandem Diabetes Care.
? Growth Drivers for Insulin Pumps: This report tells about the factors which is helping the Insulin Pump industry to grow.
? Challenges for Insulin Pumps: This report covers the problems being faced by the insulin Pump industry.

Key Companies Covered
1. Medtronic
2. Insulet Corporation
3. Tandem Diabetes Care

Countries Covered
1. United States
2. Canada
3. Germany
4. Australia
5. France
6. Netherlands
7. Switzerland
8. Sweden
9. Israel
10. United Kingdom
11. Japan

Download the full report: https://www.reportbuyer.com/product/5142066

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com  

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com  
Email: [email protected]   
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: